G. Yancey Gillespie, Ph.D.
Affiliations: | Immunology, Surgery | University of Alabama, Birmingham, Birmingham, AL, United States |
Area:
cytosine deaminase, UPRT, PNP; HSV that include TNFa, IL-2, IL-4, IL-5, IL-10, IL12, IL-16Website:
http://www.uab.edu/medicine/immunology/faculty/100-gillespieGoogle:
"G. Yancey Gillespie"Bio:
https://www.uab.edu/medicine/neurosurgery/faculty/gillespie
https://scholar.google.com/citations?user=umoHkakAAAAJ&hl=en
https://www.worldcat.org/oclc/25665506
Parents
Sign in to add mentor| Julius Major Cruse | grad student | 1971 | University of Mississippi (Cell Biology Tree) | |
| (Mediation and suppression of the primary alloimmune response in vitro: a model for immunologic enhancement) | ||||
Collaborators
Sign in to add collaborator| National Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stackhouse CT, Anderson JC, Yue Z, et al. (2022) An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases. Jci Insight |
| Boyd NH, Tran AN, Bernstock JD, et al. (2021) Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 11: 665-683 |
| Chambers MR, Bentley RT, Crossman DK, et al. (2020) The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59 |
| Bernstock JD, Vicario N, Rong L, et al. (2019) A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8: e1678921 |
| Stackhouse CT, Rowland JR, Shevin RS, et al. (2019) A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening. Cells. 8 |
| Totsch SK, Schlappi C, Kang KD, et al. (2019) Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene |
| Sin-Chan P, Mumal I, Suwal T, et al. (2019) A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 36: 51-67.e7 |
| Bernstock JD, Vicario N, Li R, et al. (2019) Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Therapy |
| Stackhouse C, Gillespie GY, Willey C. (2019) Dres-04. Long Non-Coding Rnas In Glioblastoma Tumor Recurrence And Therapy Resistance Neuro-Oncology. 21 |
| Friedman GK, Bernstock JD, Chen D, et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports. 8: 13930 |